Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs

See what CB Insights has to offer

Founded Year

1993

Stage

Acquired | Acquired

Total Raised

$2.5M

About Spectra Biomedical

Discovering and developing novel pharmaceuticals to treat neuropsychiatric and other multifactorial diseases. The unmet therapeutic needs of neuropsychiatric disorders alone have been estimated to represent an annual market potential of more than five billion dollars. Spectra believes that it can generate important pharmaceutical products for this market by applying molecular genetic technologies to clinically evaluated human DNA databases. The company has identified families that are willing to cooperate on the analysis of various disorders over a prolonged period of time. These familial samples can also be used to determine the clinical relevance of newly discovered genes. Taking this approach, Spectra has identified novel targets for the discovery of new diagnostics and therapeutics for migraine, depression, and other diseases.

Spectra Biomedical Headquarter Location

4040 Campbell Avenue Second Floor

Menlo Park, California, 94025,

United States

(650)617-9000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.